Ghost Tree Capital, LLC quarter change: USA Stocks, Reduced
In share positions in stocks (listed in the US), from the quarter ended 2024-06-30 to 2024-09-30, Ghost Tree Capital, LLC opened 8 positions, added to 15, reduced 20, sold out of 14 and left 2 unchanged. The largest increase in value was JANX (+$6,537,200); the largest decrease was BHVN (-$17,007,900).
- MLTX: Country of operation Switzerland; Class CLASS A ORD; Shares 2024-06-30 300,000; Shares 2024-09-30 128,411.
- VRDN: Country of operation United States; Class COM; Shares 2024-06-30 587,708; Shares 2024-09-30 75,000.
- SLNO: Country of operation United States; Class COM; Shares 2024-06-30 300,000; Shares 2024-09-30 150,000.
- CRBP: Country of operation United States; Class COM NEW; Shares 2024-06-30 175,000; Shares 2024-09-30 160,000.
Two Form 13F-HR filings compared (SEC CIK 1595851): 2024-06-30 (filed 2024-08-14) and 2024-09-30 (filed 2024-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move; share change is the position change.
| Stock | Country of operation | Class | Shares 2024-06-30 | Shares 2024-09-30 | Share change | Value 2024-06-30 | Value 2024-09-30 | Value change |
|---|
MLTX
MOONLAKE IMMUNOTHERAPEUTICS | Switzerland | CLASS A ORD | 300,000 | 128,411 | -171,589 | $13,191,000 | $6,474,483 | -$6,716,517 |
|---|
VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM | 587,708 | 75,000 | -512,708 | $7,646,081 | $1,706,250 | -$5,939,831 |
|---|
SLNO
SOLENO THERAPEUTICS INC | United States | COM | 300,000 | 150,000 | -150,000 | $12,240,000 | $7,573,500 | -$4,666,500 |
|---|
CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW | 175,000 | 160,000 | -15,000 | $7,918,750 | $3,300,800 | -$4,617,950 |
|---|
SYRE
SPYRE THERAPEUTICS INC | United States | COM NEW | 250,237 | 60,000 | -190,237 | $5,883,072 | $1,764,600 | -$4,118,472 |
|---|
APLS
APELLIS PHARMACEUTICALS INC | United States | COM | 135,000 | 65,000 | -70,000 | $5,178,600 | $1,874,600 | -$3,304,000 |
|---|
CRNX
CRINETICS PHARMACEUTICALS IN | United States | COM | 240,000 | 150,000 | -90,000 | $10,749,600 | $7,665,000 | -$3,084,600 |
|---|
PCVX
VAXCYTE INC | United States | COM | 150,000 | 80,000 | -70,000 | $11,326,500 | $9,141,600 | -$2,184,900 |
|---|
TGTX
TG THERAPEUTICS INC | United States | COM | 500,000 | 310,000 | -190,000 | $8,895,000 | $7,250,900 | -$1,644,100 |
|---|
ROIV
ROIVANT SCIENCES LTD | | SHS | 1,000,000 | 800,000 | -200,000 | $10,570,000 | $9,232,000 | -$1,338,000 |
|---|
CGON
CG ONCOLOGY INC | United States | COM | 260,000 | 250,000 | -10,000 | $8,208,200 | $9,432,500 | +$1,224,300 |
|---|
SVRA
SAVARA INC | United States | COM | 1,050,876 | 725,000 | -325,876 | $4,235,030 | $3,074,000 | -$1,161,030 |
|---|
CATX
PERSPECTIVE THERAPEUTICS INC | United States | COM NEW | 925,000 | 750,000 | -175,000 | $9,222,250 | $10,012,500 | +$790,250 |
|---|
IMVT
IMMUNOVANT INC | United States | COM | 260,000 | 215,000 | -45,000 | $6,864,000 | $6,129,650 | -$734,350 |
|---|
RYTM
RHYTHM PHARMACEUTICALS INC | United States | COM | 117,388 | 78,842 | -38,546 | $4,819,951 | $4,130,532 | -$689,419 |
|---|
PHAT
PHATHOM PHARMACEUTICALS INC | United States | COM | 600,000 | 375,000 | -225,000 | $6,180,000 | $6,780,000 | +$600,000 |
|---|
NGNE
NEUROGENE INC | | COM | 70,000 | 50,000 | -20,000 | $2,547,300 | $2,098,000 | -$449,300 |
|---|
OLMA
OLEMA PHARMACEUTICALS INC | United States | COM | 550,000 | 535,000 | -15,000 | $5,951,000 | $6,387,900 | +$436,900 |
|---|
PRQR
PROQR THRAPEUTICS N V | | SHS EURO | 900,000 | 887,700 | -12,300 | $1,494,000 | $1,615,614 | +$121,614 |
|---|
AXSM
AXSOME THERAPEUTICS INC | United States | COM | 150,000 | 135,000 | -15,000 | $12,075,000 | $12,132,450 | +$57,450 |
|---|
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|
| Not available yet |